Incidence of multiple primary cancers in Nagasaki atomic bomb survivors: association with radiation exposure. by Nakashima Masahiro et al.
                      1 
 
Nakashima et al. 
Research Article for Cancer Science 
 
Incidence of Multiple Primary Cancers in Nagasaki Atomic Bomb Survivors: 
Association with Radiation Exposure 
 
Short title: multiple primaries in atomic-bomb survivors 
 
Masahiro Nakashima1, Hisayoshi Kondo2, Shiro Miura3, Midori Soda5,  
Tomayoshi Hayashi6, Takeshi Matsuo7, Shunichi Yamashita4, Ichiro Sekine1,3 
 
1Tissue and Histopathology Section and 2Biostatistics Section, Division of Scientific 
Data Registry, Atomic Bomb Disease Institute, Nagasaki University Graduate School of 
Biomedical Sciences, Nagasaki, 852-8523, Japan 
3Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, 
Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8523, 
Japan 
4Department of Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki 
University Graduate School of Biomedical Sciences, Nagasaki, 852-8523, Japan 
5Radiation Effects Research Foundation, Nagasaki, 850-0013, Japan 
6Nagasaki University Hospital, Nagasaki, 852-8501, Japan  
7Nagasaki Tumor Tissue Registries, Isahaya, 859-0401, Japan 
 
Correspondence:  Masahiro Nakashima, M.D. Ph.D. 
 Tissue and Histopathology Section 
 Division of Scientific Data Registry  
 Atomic Bomb Disease Institute 
 Nagasaki University Graduate School of Biomedical Sciences 
 1-12-4 Sakamoto, Nagasaki 852-8523, Japan 
 TEL : 81-95-849-7124 
 FAX : 81-95-849-7130 
                E-mail : moemoe@nagasaki-u.ac.jp 
 
                      2 
 
Nakashima et al. 
Key words: multiple primary cancers; atomic bomb; radiation; epidemiology 
 
Abbreviations: MPC: multiple primary cancers; IR: incidence rate; RR: relative risk; 
CI: confidence interval; NTTR: Nagasaki Tumor Tissue Registries; LSS: life span study 
 
Category: Epidemiology and Prevention 
 
Brief statements: The significant finding of this study is that the atomic bomb survivors 
who had been exposed at a younger age still have a higher risk for a wide range of 
cancers, even at 62 years after the bombing. These results, on the associations between 
incidence of multiple primary cancers and atomic bombing, are described for the first 
time in this report.
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Summary 
 
To assess effects of atomic bomb radiation on incidence of multiple primary cancers 
(MPC), we analyzed the association between incidence of second primary cancers in the 
survivors of the atomic bombing of Nagasaki and exposure distance. The incidence rate 
(IR) of a second primary in MPC was calculated and stratified by the distance from the 
hypocenter and age at the time of bomb for the years 1968 through 1999. The IR of first 
primary was also calculated and compared with second primary to determine whether 
atomic bomb radiation was associated with the multiplicity of the tumors. There were 
511 confirmed cases of MPC in the 7,572 cancer-bearing survivors. The crude IR was 
27.6 per 100,000 person-years. The IR of second primaries significantly decreased with 
increasing distance from the hypocenter: relative risk (RR), 0.89 per 1.0 km; 95% 
confidence interval (CI), 0.84-0.94. A significant decrease was also noted for those of 
older ages at the time of the bombing based on the attained age of second primary: RR, 
0.91 per 1 year; 95% CI, 0.90-0.92. These findings suggested the radiation effects on 
MPC. Furthermore, when compared with the first primary, a stronger distance effect 
was suggested on the occurrence of a second primary in the survivors. This study 
suggests the significance of atomic bomb radiation on MPC in the survivors. These 
results, on the incidence of MPC in the tumor-bearing survivors and its correlations 
with the atomic bombing of 62 years ago, are described for the first time in this report.
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Introduction 
 
 Sixty-two years have now elapsed since two atomic bombs were exploded on 
Hiroshima and Nagasaki, Japan on August 6 and 9, 1945. The average age of the 
survivors has now reached 75 years. Several types of leukemia showed the highest 
incidence in the 5 to 10 year period after the atomic bomb explosions. Meanwhile, an 
increased risk of cancers has continued for decades, and the incidences of certain types 
of cancers are still higher than in controlled populations.(1-3) The occurrence of multiple 
primary cancers (MPC) is considered to be a reflection of systematic exposure to 
environmental carcinogens or of a predisposition to cancer. The association of radiation 
exposure from the atomic bomb and the development of MPC has not yet been studied, 
but is of interest in terms of learning more about the effects of whole-body irradiation 
on carcinogenesis. To elucidate the late carcinogenic effects of atomic bomb radiation 
on the survivors, the association between the incidence of MPC in survivors and 
exposure distance from the hypocenter has been analyzed. This study was conducted to 
provide insights into the etiology of cancer among the survivors and also to collect 
important information for medical care of the atomic bomb survivors and other victims 
of radiation-associated accidents around the world. 
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Subjects and Methods 
 
Subjects 
 A series of clinical data were available on 91,890 subjects including 54,915 
females and 36,975 males of the survivors registered at the Division of Scientific Data 
Registry, Atomic Bomb Disease Institute, Nagasaki University Graduate School of 
Biomedical Sciences, which was established in 1972. The registry of clinical data on 
Nagasaki survivors was started in 1968. This population was confined to residents in 
Nagasaki city who were directly exposed by the atomic bomb and used as a 
denominator. A survivor was defined in the present study as a person who received the 
“Atomic Bomb Survivor’s Health Handbook” produced by Nagasaki city authorities 
since the establishment of the Atomic Bomb Survivors’ Medical Treatment Law in 
April 1957. All information including exposure distance had been recorded before this 
study. 
 To examine malignancy cases in survivors, we used a database by the Nagasaki 
Tumor Tissue Registries (NTTR), which was established in 1974. This data base 
included 301,673 cases of tissue registration based on pathological reports of patients 
living in south Nagasaki prefecture including Nagasaki city since 1961 through 1999. 
The registered database included patient age, gender, tumor site, histological diagnosis, 
and date of diagnosis. These data were linked to the survivors’ database since 1968 to 
identify survivors having suffered from malignancy. The experimental protocol was 
approved by the Ethics Review Committee of Nagasaki University Graduate School of 
Biomedical Sciences (Protocol No. 0305150036). 
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To identify MPC in atomic bomb survivors 
 A retrospective search of the database for MPC was conducted according to 
following criteria: i) multiple (two or more) primaries occurring in different organs, ii) 
multiple lesions of different histological types occurring in paired organs but apparently 
different sites (e.g. adenocarcinoma of left lung and small cell carcinoma of right lung, 
ductal carcinoma of left breast and lobular carcinoma of right breast), iii) multiple 
lesions of the same histological type occurring in paired organs are not counted as a 
MPC but as a single primary, iv) multiple primaries occurring in the colorectum but 
apparently different sites (e.g. ascending and sigmoid colon). A series of 
immunohistochemical studies were used with site-related antibodies, including 
cytokeratins 7 and 20, thyroid transcription factor-1, CA125, prostate specific antigen, 
estrogen receptor, progesterone receptor, etc., to carefully differentiate primary or 
metastatic cancers (e.g. colorectal and lung cancers, colon/gastric cancer and ovarian 
cancers, prostatic/uterine and rectal cancers). 
 
To evaluate the association between MPC and atomic bomb radiation 
 In this study, an event of MPC in each survivor was considered to occur with a 
pathological diagnosis of two first primaries in synchronous case/second primary in 
metachronous case. Person-years of observation were cumulative from the date when 
the individual survivor’s data was registered in our database until the earliest date at 
diagnosis of two first primaries in a synchronous case/second primary in a 
metachronous case, date of death, the end of follow-up (date when survivors moved 
outside of Nagasaki city), or the end of study (31 December 1999). Then, the incidence 
rate (IR) of MPC per 100,000 person-years among atomic bomb survivors including 
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healthy individuals was calculated by stratification of the distance from the hypocenter 
(0-1.0, 1.1-1.5, 1.6-2.0, 2.1-2.5, 2.6-3.0, >3.0km) and age at the time of bombing (0-9, 
10-19, 20-29, 30-39, ≥40). Furthermore, the IR of second primaries per 100,000 
person-years among atomic bomb survivors who had experienced the first primary was 
calculated exactly in the same way as mentioned above, and compared with the IR of 
first primaries to clarify whether atomic bomb radiation was associated with the 
multiplicity of tumors. 
 The exposure distance was used as a substitute for the estimated irradiated dose. 
Actually, several unique epidemiological studies on Nagasaki survivors have already 
been documented with exposure distances.(4-9) In general, survivors who were less than 
1.5 km from the hypocenter were exposed to a significant dose of radiation. The 
estimated doses in Nagasaki survivors who were not shielded at the time of explosion 
are: 924.7 cGy at 1.0 km, 120.7 cGy at 1.5 km, 17.9 cGy at 2.0 km, and 2.9 cGy at 2.5 
km from the hypocenter.(7)  
 
Statistical analyses 
 The effects of change in exposure distance, age at the time of bombing, and gender 
on the IR of second/first primary in survivors was evaluated using a Cox proportional 
hazard model. The Cox model is a robust, semiparametric method for modeling 
time-to-event data in the presence of censored cases to assess the effect of independent 
predictor variables. The following predictor variables were used in the model: exposure 
distance, age at the time of bombing, and gender. An event was considered to occur 
with the development of second/first primary. A comparison of IR between the two 
groups (younger vs. older attained age-range, first vs. second primary) was performed 
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by the relative risk (RR) with 95% confidence interval (CI). The PHREG procedure in 
the SAS 8.2 software (SAS Institute, Cary, NC, USA) was utilized for calculation. All 




The IR of MPC among atomic bomb survivors and its association with exposure 
distance/age at the time of bombing/gender 
 Overall 91,890 survivors have been followed for 1,850,046 person-years during 
which a total of 511 MPC cases comprised of 242 females and 269 males were 
confirmed. Of the 511 MPC cases, 473 (92.6%) were double, 29 (5.7%) were triple, 8 
(1.6%) were quadruple, and 1 (0.2%) was quintuple. The crude IR of MPC was 27.6 per 
100,000 person-years in the overall study population. Both person-years and crude IR of 
MPC by gender and exposure distance are shown in Table 1. The IR of MPC 
significantly decreased as distance increased from the hypocenter [RR per 1.0km 
increment: 0.89, 95% CI: 0.84-0.94]. Simultaneously, an age effect was observed in the 
IR of MPC, because the incidence significantly decreased with older age at the time of 
bomb based on respective attained-age range [RR per 1 year increment in the overall 
study population: 0.91, 95% CI: 0.90-0.92]. When analyses were stratified by gender, 
the IR of MPC was significantly higher in males than in females [overall RR vs. male: 
0.40, 95% CI: 0.34-0.48]. However, contrary to that noted in the overall population, in 
younger attained-age range less than 50-yo, IR of MPC was significantly higher in 
females than in males [RR vs. male: 3.16, 95% CI: 1.04-9.60]. RRs for the IR of MPC 
in survivors by exposure distance, age at the time of bombing, and gender in respective 
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attained age-range are summarized in Table 2. 
 MPC can be divided into synchronous and metachronous groups depending on the 
interval between their diagnoses. The MPC cases determined by the interval between 
the first and second primaries are summarized in Table 3. Of the 511 MPC cases, 331 
cases (64.8%) had two primaries within the 5-year interval (short-term). Of these, there 
were 82 synchronous cases (16.0%) and 249 short-term metachronous cases (48.8%). 
The IRs of short-term MPC by the exposure distance and age at the time of bombing 
were also calculated. The IR of short-term MPC significantly decreased with increased 
distance from the hypocenter [RR per 1.0km increment: 0.91, 95% CI: 0.85-0.98] and, 
simultaneously, significantly decreased with older age at the time of bombing based on 
the attained age of MPC [RR per 1 year increment: 0.92, 95% CI: 0.90-0.93].  
 
Associations between the IR of second primary in metachronous cases and exposure 
distance/age at the time of bombing/gender, and their comparisons with first primary  
 In our cohort, 7,572 survivors were found who had suffered from a malignancy. 
Overall 7,572 survivors bearing a first primary were followed for 193,274 person-years 
during which a total of 429 second primary cases (in which 82 synchronous cases were 
excluded) that included 217 females and 212 males were confirmed. The crude IR of 
second primaries was 222.0 per 100,000 person-years in the survivors bearing first 
primary, whereas that of a first primary was 419.0 per 100,000 person-years in the 
overall study population (Table 4). The IRs of second and first primaries categorized by 
gender and exposure distance are presented in Table 4. The IRs of both second and first 
primaries significantly decreased as distance increased from the hypocenter [overall RR 
per 1.0km increment: 0.86 and 0.97, 95% CI: 0.80-0.92 and 0.96-0.98, respectively] 
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(Table 5). By compariing overall RR per 1.0km increment between the second and first 
primary, a stronger distance effect was suggested on the occurrence of second primary. 
Simultaneously, an age effect was observed in the IRs of both second and first primary, 
because the incidence significantly decreased with older age at the time of bombing 
based on the respective attained-age range [overall RR per 1 year increment: 0.96 and 
0.96, 95% CI: 0.95-0.98 and 0.96-0.97, respectively] (Table 5). Furthermore, the IRs of 
both second and first primaries were significantly higher in males than in females 
[overall RR vs. male: 0.46 and 0.58, 95% CI: 0.38-0.56 and 0.55-0.60, respectively] 
(Table 5). However, contrary to that in the overall population, in the younger 
attained-age group less than 50-yo, the IRs of both second and first primaries were 
higher in females than in males [RR vs. male: 2.50 and 1.53, 95% CI: 0.80-7.87 and 
1.31-1.79, respectively] (Table 5). 
 
Sites of second and first primary 
 A wide range of cancers was observed in both second and first primaries. Sites of 
second primary (in which 82 synchronous cases were excluded) by gender and 
attained-age are presented in Table 6. The most prominent sites for second primary 
included the breast and lung (n=3, 21.4%, each) in younger attained-age group (n=14), 
while colon (n=84, 20.2%) and stomach (n=80, 19.3%) were followed by lung (n=50, 
12.0%) in the older attained-age group (n=415). The most prominent sites for first 
primary included the stomach (n=162, 23.1%) following breast (n=121, 17.3%) and 
uterine cervix (n=111, 15.9%) in the younger attained-age group (n=700), while 
stomach (n=1713, 25.2%) and colon (n=917, 13.5%) were in the older attained-age 
group (n=6790). 
                      11 
 
Nakashima et al. 
DISCUSSION 
 In general, the population-based systematic studies on the incidence of MPC have 
been carried out by long standing cancer registries, because a huge cohort of cancer 
patients has to be followed to identify MPC cases. However, a previous report showed a 
modification of the risk of developing MPC in cancer patients in comparison with the 
general population.(10) The cohort studied showed an approximately 10% reduced risk 
of developing further cancers in comparison with the general population when only 
second metachronous cancers were considered. In contrast, the inclusion of 
synchronous cases resulted in an approximately 10% increased risk. MPC is defined as 
two or more independent primary cancers arising in the same individual, and their 
existence of does not depend on time. Therefore, synchronous MPC should be included 
in a study on MPC incidence, and could be diagnosed not only in cancer patients but 
could also be present in cancer-free patients before the diagnosis. We carefully 
reviewed each case with a series of immunohistochemistry to determine whether each 
malignancy is primary or metastatic and, finally, identified 82 synchronous cases 
(16.0%) from a total 511 MPC in Nagasaki survivors who suffered direct exposure. 
Because the main purpose of this study was to clarify the significance of atomic bomb 
radiation on the multiplicity of tumors, we could not exclude these synchronous cases in  
calculating the IR of MPC among overall survivors. Simultaneously, the IR of a second 
primary, excluding synchronous cases among survivors who had experienced a first 
primary, was calculated. This IR was then compared with that of the first primary to 
determine whether atomic bomb radiation was associated with the multiplicity of the 
tumors. This study points out the significance of atomic bomb radiation on the 
occurrence of MPC in the survivors. Furthermore, compared with first primary, the 
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higher increased risk for the development of a second primary was noted in the 
survivors who were exposed at a closer distance, again suggesting the association of 
atomic bomb radiation on the occurrence of MPC. These results dealing with the 
incidence of MPC and its associations with the atomic bombing of 62 years ago are 
described for the first time in this report. 
 In a previous Japanese report, the incidence of MPC in Nagasaki survivors was 
examined with cases registered at the NTTR during the period from 1973-1977.(4) These 
cases should be a part of the cohort in our present study, but no significance of atomic 
bomb radiation exposure in the incidence of MPC was found in those Nagasaki 
survivors.(4) The increased risk for MPC seems to begin more recently than that for 
single cancers. It is quite plausible that the survivors who had been exposed at younger 
ages have already reached the cancer-prone age to develop the cancers in multiple 
organs. Thus, the atomic bombing of 62 years ago is still increasing the cancer risks in 
survivors, particularly for those exposed at a closer distance and younger age. 
 We found a higher incidence for both second and first primaries in males than in 
females in the overall population. In contrast, RRs for both second and first primaries 
were significantly higher in females than in male among the younger attained-age group. 
This is quite likely because female-specific cancers such as breast and uterine cervix are 
most prominent in the younger attained-age group, while stomach and colon cancers, 
which are not gender specific but typically show higher risks for their incidences in 
males than in female, are most prominent in the older attained-age group. 
 Radiotherapy and chemotherapy for the first primary might be associated with an 
increased risk of developing a second primary.(11) Our analysis did not control for 
treatment differences. However, the effect of treatment on a subsequent primary would 
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be negligible in short-term MPC, because studies of treatment–associated risk for 
second primaries typically had at least a 10-15 year interval between the two 
tumors.(12,13) Reports on large populations of patients, who have been exposed to cancer 
treatments in childhood, have shown that the cumulative probability of a second cancer 
can be quite low.(14) Also, other reports suggested that only about 1% of the long-term 
follow-up patients developed a second malignancy after treatment for the first primaries 
with an interval of 82-136 months.(15,16) Thus, mechanisms other than those related 
therapy should be postulated for the development of the second primary in short-term 
MPC. In our study, 64.8% cases were short-term MPC, while only 16.4% cases were 
metachronous MPC with more than a 10-year interval. Our statistical analyses 
demonstrated a significant high incidence of short-term MPC in the survivors exposed 
at closer distance and younger age at the time of bombing. These results also provide 
evidence for the involvement of atomic bomb radiation in MPC among the survivors. 
 Our data suggest that the survivors, particularly for those who were exposed at a 
younger age, still have a high risk for cancers in multiple organs even at the present 
time. Although it is now 62 years since the atomic bomb explosions, we do not know 
the crucial mechanisms that can explain the continuously higher incidence of cancers in 
atomic bomb survivors for decades. It is noteworthy that according to our data base, the 
number of atomic bomb survivors living in Nagasaki city was 49,250 (39.4 % of 
Nagasaki A-bomb survivors) at the end of 2005. Furthermore, most of them were 
exposed as children in 1945. Thus, a higher risk of MPC, as a late effect of atomic 
bomb radiation, still persists in the survivors. We believe that further research on MPC 
in the survivors can contribute to an understanding of both radiation-associated 
carcinogenesis and a predisposition to cancers. 
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Table 1. The crude incidence rates of multiple primary cancers in Nagasaki 
atomic-bomb survivors by gender and exposure distance by each factor. 
 
 




Female Male Total 
PY Cases IR PY Cases IR PY Cases IR 
Second primary 
≤1.0 24,516 18 73.4 17,274 6 34.7 41,790 24 57.4
1.1-1.5 54,688 22 40.2 43,027 35 81.3 97,715 57 58.3
1.6-2.0 98,570 18 18.3 62,712 24 38.3 161,282 42 26.0
2.1-2.5 121,270 28 23.1 73,444 18 24.5 194,714 46 23.6
2.6-3.0 148,996 36 24.2 86,980 30 34.5 235,976 66 28.0
3.0< 700,200 120 17.1 418,369 156 37.3 1,118,569 276 24.7
Overall 1,148,240 242 21.1 701,806 269 38.3 1,850,046 511 27.6
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Table 2. Relative risks and 95% confidence intervals for the incidence rate of multiple 




ATB: age at the time of bomb, RR: relative risk, CI: confidence intervals  
a: per 1km increment, b: per 1-year increment, c: vs. male 
*: The attained-age of multiple primary cancers was defined as age at a pathological 





Exposure distance ATB Female 
RRa 95% CI RRb 95% CI RRc 95% CI 
<50 18 0.82 0.59-1.14 0.96 0.88-1.04 3.16 1.04-9.60 
50-59 73 0.91 0.79-1.05 0.91 0.88-0.94 0.55 0.35-0.88 
60-69 182 0.89 0.81-0.98 0.91 0.89-0.93 0.43 0.32-0.57 
70-79 148 0.86 0.76-0.96 0.90 0.88-0.92 0.35 0.25-0.48 
80+ 90 0.92 0.80-1.07 0.91 0.89-0.94 0.26 0.17-0.40 
Overall 51l 0.89 0.84-0.94 0.91 0.90-0.92 0.40 0.34-0.48 
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Table 3. Number of multiple primary cancers in Nagasaki atomic-bomb survivors by 
gender and interval between the first and second primary. 
 
Interval (y) Female Male Total 
Synchronous 25 (4.9%) 57 (11.2%) 82 (16.0%) 
<1 38 (7.4%) 42 (8.2%) 80 (15.7%) 
1-2 22 (4.3%) 31 (6.1%) 53 (10.4%) 
2-3 29 (5.7%) 23 (4.5%) 52 (10.2%) 
3-4 11 (2.2%) 24 (4.7%) 35 (6.9%) 
4-5 17 (3.3%) 12 (2.4%) 29 (5.7%) 
Short-term* 142 (27.8%) 189 (36.9%) 331 (64.8%) 
5-10 46 (9.0%) 50 (9.8%) 96 (18.8%) 
10< 54 (10.6%) 30 (5.9%) 84 (16.4%) 
Total 242 (47.4%) 269 (52.6%) 511 (100%) 
 
*Synchronous and short-term metachronous multiple primary cancers which was 
defined as two primaries within 5-year interval.  
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Table 4. The crude incidence rates of second primary and first primary in Nagasaki 
atomic-bomb survivors in respective exposure distance. 
 
 
PY: person-years, IR: incidence rate
Distance 
(km) 
Female Male Total 
PY Cases IR PY Cases IR PY Cases IR 
Second primary 
≤1.0 2,654 18 678.3 2,624 5 190.5 5,278 23 435.8
1.1-1.5 6,704 21 313.2 7,643 32 418.7 14,347 53 369.4
1.6-2.0 9,287 16 172.3 7,361 17 230.9 16,648 33 198.2
2.1-2.5 11,660 23 197.2 8,985 13 144.7 20,646 36 174.4
2.6-3.0 13,586 29 213.5 10,904 26 238.5 24,490 55 224.6
3.0< 64,801 110 169.7 47,063 119 252.9 111,865 229 204.7
Overall 108,692 217 199.6 84,580 212 250.6 193,274 429 222.0
First primary 
≤1.0 23,762 112 471.3 16,818 109 648.1 40,580 221 544.6
1.1-1.5 52,772 245 464.3 416,78 325 779.8 94,450 570 603.5
1.6-2.0 96,178 354 368.1 61,349 294 479.2 157,527 648 411.4
2.1-2.5 118,289 454 383.8 71,780 347 483.4 190,069 801 421.4
2.6-3.0 145,638 532 365.3 84,991 474 557.7 230,629 1,006 436.2
3.0< 683,498 2,434 356.1 410,450 1,892 461.0 1,093,947 4,326 395.4
Oveall 1,120,137 4,131 368.8 687,066 3,441 500.8 1,807,202 7,572 419.0
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Table 5. Comparisons of relative risks and 95% confidence intervals for the incidence of 
second primary and first primary in Nagasaki atomic-bomb survivors by each factor in 
respective attained age-range. 
 
 
ATB: age at the time of bomb, RR: relative risk, CI: confidence intervals  
a: per 1km increment, b: per 1-year increment, c: vs. male 
*: The attained-age of second/first primary was defined as age at the pathological 




Exposure distance ATB Female 
RRa 95% CI RRb 95% CI RRc 95% CI 
Second primary  
<50 15 0.79 0.55-1.14 0.94 0.86-1.04 2.50 0.80-7.87 
50-59 59 0.85 0.72-1.00 0.89 0.86-0.93 0.69 0.41-1.15 
60-69 151 0.84 0.75-0.94 0.91 0.88-0.93 0.49 0.35-0.67 
70-79 126 0.86 0.75-0.97 0.89 0.86-0.91 0.39 0.27-0.56 
80+ 78 0.92 0.78-1.08 0.91 0.88-0.95 0.30 0.19-0.47 
Overall 429 0.86 0.80-0.92 0.96 0.95-0.98 0.46 0.38-0.56 
First primary  
<50 702 0.97 0.93-1.02 1.02 1.00-1.03 1.53 1.31-1.79 
50-59 1,577 0.97 0.94-1.00 0.97 0.97-0.98 0.72 0.65-0.79 
60-69 2,387 0.97 0.95-1.00 0.97 0.96-0.97 0.50 0.46-0.55 
70-79 1,881 0.98 0.95-1.01 0.95 0.95-0.96 0.43 0.39-0.47 
80+ 1,025 0.94 0.90-0.98 0.95 0.94-0.95 0.51 0.45-0.58 
Overall 7,572 0.97 0.96-0.98 0.96 0.96-0.97 0.58 0.55-0.60 
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<49 >50 <49 >50 <49 >50 
Oral cavity 
& pharynx 
0 2 (1.0) 2 (0.9) 1 (25.0) 2 (1.0) 3 (1.4) 1 (7.1) 4 (1.0) 5 (1.2)
Nose & larynx 0 0 0 0 5 (2.4) 5 (2.4) 0 5 (1.2) 5 (1.2)
Lung 3 (30.0) 22 (10.6) 25 (11.5) 0 28 (13.5) 28 (13.2) 3 (21.4) 50 (12.0) 53 (12.4)
Esophagus 0 3 (1.4) 3 (1.4) 0 10 (4.8) 10 (4.7) 0 13 (3.1) 13 (3.0)
Stomach 1 (10.0) 40 (19.3) 41 (18.9) 0 40 (19.2) 40 (18.9) 1 (7.1) 80 (19.3) 81 (18.9)
Colon 0 45 (21.7) 45 (20.7) 2 (50.0) 39 (18.8) 41 (19.3) 2 (14.3) 84 (20.2) 86 (20.0)
Rectum 1 (10.0) 16 (7.7) 17 (7.8) 0 20 (9.6) 20 (9.4) 1 (7.1) 36 (8.7) 37 (8.6)
Liver 0 4 (1.9) 4 (1.8) 1 (25.0) 12 (5.8) 13 (6.1) 1 (7.1) 16 (3.9) 17 (4.0)
Gallbladder 
& bile duct 
0 2 (1.0) 2 (0.9) 0 3 (1.4) 3 (1.4) 0 5 (1.2) 5 (1.2)
Pancreas 0 2 (1.0) 2 (0.9) 0 1 (0.5) 1 (0.5) 0 3 (0.7) 3 (0.7)
Urinary tract 
& bladder   
0 7 (3.4) 7 (3.2) 0 10 (4.8) 10 (4.7) 0 17 (4.1) 17 (4.0)
Kidney 0 1 (0.5) 1 (0.5) 0 2 (1.0) 2 (0.9) 0 3 (0.7) 3 (0.7)
Thyroid 0 5 (2.4) 5 (2.3) 0 0 0 0 5 (1.2) 5 (1.2)
Breast 3 (30.0) 15 (7.2) 18 (8.3) 0 0 0 3 (21.4) 15 (3.6) 18 (4.2)
Cervix 1 (10.0) 3 (1.4) 4 (1.8) 1 (7.1) 3 (0.7) 4 (0.9)
Endometrium 0  7 (3.4) 7 (3.2) 0 7 (1.7) 7 (1.6)
Ovary 1 (10.0) 4 (1.9) 5 (2.3) 1 (7.1) 4 (1.0) 5 (1.2)
Prostate   0 17 (8.2) 17 (8.0) 0 17 (4.1) 17 (4.0)
Testis   0 0 0 0 0 0 
Skin 0 17 (8.2) 17 (7.8) 0 7 (3.4) 7 (3.3) 0 24 (5.8) 24 (5.6)
Hematopoietic 0 7 (3.4) 7 (3.2) 0 9 (4.3) 9 (4.2) 0 16 (3.9) 16 (3.7)
Brain 0 2 (1.0) 2 (0.9) 0 0 0 0 2 (0.5) 2 (0.5)
Others 0 3 (1.4) 3 (1.4) 0 3 (1.4) 3 (1.4) 0 6 (1.4) 6 (1.4)
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